🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Focal segmental glomerulosclerosis refers to a pattern of glomerular injury but also includes primary FSGS which is considered as an immune mediated glomerulopathy. This study found that Primary FSGS accounted for 16.6% of biopsy-proven FSGS. bit.ly/CJASN0590 Min Zhuo

Unedited love song for the kidneys during #nephjc party #kidneywk All the applause go to Timothy Yau

Our main paper from the H3Africa Kidney Disease Network just got published in New England Journal of Medicine! Congratulations 🎉 to all the authors… it has been many years of hard work...Glad to be part of the H3AKN… African Association of Nephrology (AFRAN) Int Society of Nephrology Indian Society of Nephrology ERA - European Renal Association SLANH

B-cell activating factor and A proliferation-inducing ligand play key roles in the pathogenesis of IgA nephropathy. This study found that atacicept treatment reduced Gd-IgA1, hematuria, and UPCR with stabilization of eGFR through 96 weeks. bit.ly/JASN0541 #KidneyWk #LBCT

🔔Early bird registration for the “Rare Kidney Disease” conference is open until October 31. Don’t wait until the last minute; click the link below and grab your spot before it disappears faster than a kidney bean at a chili cook-off! 🫘😁 eeds.com/portal_live_ev… ➡️Free for

Intensive Home Blood Pressure Lowering in Patients with Advanced CKD buff.ly/4dX3LiK tcope.land Divya Seth Raymond Hsu #CKD UCSF Nephrology

Rituximab or Cyclophosphamide? ANCA #Vasculitis #ACR24 guidelines conditionally recommend RTX over CYC for remission induction in SEVERE disease Consider CYC if - Intolerance to RTX - Worsening disease - Fulminant disease (renal, ventilated) #MedTwitter #Rheumatology

T3g #nephjc ACCORD: No CV benefit from intensive BP control in T2D SPRINT:⬇️CV risk in non-DM pts with intensive BP control ESPRIT:⬇️ CV events with intensive BP control, regardless of DM history BPROAD: benefit in DM pts, ⬇️ stroke (HR 0.79, 0.67–0.92), NO diff in all-cause ☠️

A packed house today! #IgAN discussion happening now. #Rarekidneydisease conference #PalmSprings GlomCon Dana Rizk Raymond Hsu Kirk Campbell ✨ panelists!

Look at our panel of experts for the lupus nephritis clinic session ⭐️⭐️⭐️ Richard J. Glassock Aisha Shaikh Poyan Mehr Raymond Hsu ⭐️⭐️⭐️ #RKDC

Thank you Sayna Norouzi, MD, FASN and Amir Abdipour, MD, FASN for hosting the Rare Disease Symposium. Great talks & discussions. It was wonderful to connect with so many amazing people Fouad Chebib, MD, FASN Richard J. Glassock Dana Rizk Susanne Nicholas Silvi Shah, MD, MS Poyan Mehr Raymond Hsu

🚨 The #REGENCY phase 3 trial of #obinutuzumab in #Lupus #nephritis has just been published in the NEJM!!! DOWNLOAD LINK: nejm.org/doi/full/10.10…

Do you have fibrillary glomerulonephritis? You may be eligible for a clinical trial that is studying a novel therapy for fibrillary glomerulonephritis. For more information, please visit mayocl.in/4l2a35u

#GlomConHawaii 2025 🌴🌊 session: Surrogate Endpoints and Biomarkers for Glomerular Diseases Participants will discuss surrogate endpoints and biomarkers, emphasizing their role in trial design, patient stratification, and regulatory acceptance. Register here 👉

We're pleased to present the expert speakers and panelists for the upcoming Workshop on Building Glomerular Disease Clinics, an initiative supporting nephrologists in establishing and sustaining GN Clinics. This workshop builds on the momentum of last year's event and the

Congratulations to fellow, Dr. Daniel Gauvin (Daniel Gauvin), selected by UCSF IM Residents as the Fellow of the Year for the Nephrology Fellowship!

❗️Check out the latest breakthroughs in Nephrology from the past year: 💥 CKD: Finerenone and SGLT2 inhibitors are leading the way! 💥 Glomerulonephritis: A wave of innovative therapies for IgA Nephropathy! 💥 Dialysis: Updates on volume management, cannulation techniques, and

BREAKTHROUGH in #IgAN care! In the Phase 3 VISIONARY study, Sibeprenlimab 400 mg delivered a staggering –50.2% reduction in 24h uPCR at 9 months vs placebo’s +2.1% (placebo-adjusted 51.2% effect; 96.5% CI 42.9-58.2%; P < 0.0001)! #ERA25 #BeyondNephrology

Congrats to our Renal Transplant fellows Drs. Jaclyn Khil and Victor Prado graduating from our transplant fellowship! We had a great night of laughter and celebration of your accomplishments! Best of luck with your future endeavors!

Celebrating another successful year of our GN Club with fellows and faculty UCSF Nephrology